- New
- Research Article
- 10.61409/v73046
Tuberøse xantomer
- Oct 27, 2026
- Ugeskrift for laeger
- Tanja Todberg + 3 more +3
Publications from 2021 to 2026
Showing 10 of 271 papers
Tuberøse xantomer
Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - A randomized controlled trial.
Renal cell carcinoma (RCC) primarily affects older adults who often present with frailty, increasing their risk of surgical complications and delayed recovery. Prehabilitation, incorporating exercise, nutrition, and psychological support, may improve postoperative outcomes. However, no studies have investigated prehabilitation prior to surgery for RCC. The aim is to assess whether a one-month multimodal prehabilitation program including geriatric interventions improves recovery in patients with frailty undergoing surgery for localized RCC≤7cm. 60 patients, aged ≥65, with a Clinical Frailty Scale (CFS) score of 3-6 are randomized 1:1 to standard care or prehabilitation involving home-based exercise, geriatric assessment with tailored interventions, and smoking cessation support. The primary outcome is change in Quality of Recovery-15 (QoR-15) 21days postoperatively. Secondary outcomes include changes in QoR-15, health-related quality of life (EQ-5D-5L) and physical performance (30-s chair-stand test, handgrip strength) assessed preoperatively, 1, 21 and 90days postoperatively. Postoperative complications will be evaluated using the Clavien-Dindo classification, alongside a cost-effectiveness analysis. Long-term outcomes include 1- and 5-year recurrence-free, cancer-specific, and overall survival. Pre-KiT explores if a pragmatic geriatric prehabilitation strategy is effective and feasible for older frail patients with RCC. The intervention is designed for easy implementation in clinical practice: administered by a single healthcare professional, requiring only one additional hospital visit, and consists of home-based exercises. This low-resource approach also aims to minimize financial costs, which is of importance for implementation possibilities. If successful, it could improve standard care and outcomes after surgery. ClinicalTrials.gov ID: NCT06745609. Prospectively registered December 12th, 2024.
Read moreChronic pulmonary aspergillosis as a complication of lung cavities and prednisolone treatment
This case report describes a 68-year-old woman with COPD and emphysema who developed persistent lung cavities following severe community-acquired pneumonia. She subsequently received repeated courses of prednisolone due to clinical suspicion of an organising process, suspected recurrence thereof, and COPD exacerbations. The patient developed chronic cavitary pulmonary aspergillosis, confirmed by imaging and microbiology. She responded well to long-term azole therapy, with both radiological and symptomatic improvement, as well as normalisation of Aspergillus fumigatus IgG.
Read moreSaliva phosphorylated tau concentration is not associated with Alzheimer’s disease, cerebrospinal fluid or blood biomarkers
ObjectiveOne of the most challenging aims of the scientific community in the last decade, is to find an easily accessible matrix in which neurodegeneration-related biomarkers can be measured and used to diagnose Alzheimer’s disease (AD) in vivo. Blood biomarkers have led the way in this regard, specifically, phosphorylated tau (p-tau) which demonstrates excellent diagnostic and prognostic properties. The recent success of the blood biomarkers for AD pathophysiology poses a new question – can p-tau be measured in other peripheral and even more accessible biofluids, and do they have relation to disease? Saliva contains biomarkers linked to neurodegeneration and it has been proposed as a potential sample type that would be minimally invasive to collect for this purpose.MethodsIn this study, we confirmed the presence of several p-tau species in saliva fluid and saliva gland tissue by Immunoprecipitation-Mass spectrometry (IP-MS) and immunohistochemistry, respectively. Furthermore, we measured saliva and plasma p-tau181 concentrations in 125 memory clinic participants, using ultrasensitive Single molecule array (Simoa) technology.ResultsDespite a weak correlation between saliva p-tau181 and CSF t-tau (rho = 0.13, p < 0.01), there were no significant differences in saliva p-tau181 concentration between the different clinical groups and the healthy controls.InterpretationFor this reason, we conclude that saliva p-tau181 is not acceptable as a biomarker for AD.
Read moreEpcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial
A randomized study of ropeginterferon in combination with bosutinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic Phase. the bosupeg trial from the Nordic CML study group
Targeted Screening for Congenital Cytomegalovirus in the Newborn Hearing Screening Program: A Population-Based Cohort Study.
To diagnose newborn infants with congenital cytomegalovirus (cCMV) related sensorineural hearing loss (SNHL) within the critical four-week window for initiating antiviral treatment, we aimed to determine the number needed to test (NNT) for cCMV among newborn infants failing the neonatal hearing screening. A population-based multicenter cohort study included newborn infants in East Denmark who failed two hearing screening tests and underwent saliva CMV screening between November 2021 and May 2024. The NNT was calculated as the inverse of the absolute detection rate of cCMV-related SNHL in this cohort. A total of 484 infants with hearing screening failure were tested for cCMV. Of these, 27 (5.6%) were CMV positive in saliva and 7 (1.5%) were confirmed to have cCMV in urine, blood, or dried blood spots. Six (85.7%) of 7 infants with cCMV and initial hearing screening failure had normal hearing at follow-up, leaving 1 (0.2%) of 484 with cCMV-related SNHL and an NNT of 484 (95% CI 87-20 000). In our setting, targeted screening for cCMV resulted in a high NNT of almost 500 to identify one newborn infant with cCMV-related SNHL, reflecting a low incidence of cCMV-related SNHL and a high risk of false-positive hearing screening.
Read moreFrailty should be assessed before surgery
The surgical population is ageing, and preoperative surgical evaluation is limited in its risk prediction ability of perioperative complications. Increasing age results in an increased risk of frailty. Guidelines suggest that frailty should be assessed before surgery. Different frailty scales are described as suggestions for risk-stratification. The frail patient should be offered shared decision-making prior to surgery. Preoperative optimisation programs, i.e. prehabilitation, may benefit patients with frailty, but further research studies examining these perspectives are warranted, as argued in this review.
Read moreEfficacy of Dupilumab in Patients with Severe Asthma and Co-existing COPD
<bold>Introduction:</bold> Dupilumab, a monoclonal antibody targeting IL4-Rα, has demonstrated efficacy in reducing exacerbations in both severe asthma (SA) and chronic obstructive pulmonary disease (COPD). SA is often late-onset, and many patients have coexisting COPD. These patients are, however, generally excluded from clinical trials, and hence little is known about their benefit from anti-IL4-Rα therapy. <bold>Aim:</bold> Compare treatment responses to anti-IL4-Rα therapy in patients with combined SA+COPD, versus patients with SA only. <bold>Methods:</bold> The Danish Severe Asthma Register is a complete nationwide prospective cohort of patients with SA receiving biologics. All patients with at least one year of complete follow-up were included, and stratified according to coexisting COPD, defined as forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 0.70, a tobacco exposure of at least 10 pack-years and age > 40 yr. <bold>Results:</bold> A total of 161 patients were included, 44% (71 patients) had co-existing COPD. After 12 months of therapy, the mean reduction in exacerbations was comparable among SA+COPD vs SA only patients: 67.0% (SD=40.6) vs 67.5% (50.4), p=0.95. Mean mOCS daily dose was reduced by 3.1mg (3.0) in SA+COPD and 4.7mg (7.1) in SA, p=0.35. Mean ACQ-6 score improved by 1.0 (1.4) in SA+COPD vs. 1.1 (1.2) in SA only, p=0.80. However, the proportion of patients with a complete response (no exacerbations and no mOCS after 12 months) tended to be less among SA+COPD patients (45% versus 61%, p=0.07). <bold>Conclusion:</bold> Comorbid COPD in patients with SA is common and does not reduce the efficacy of dupilumab on exacerbations, mOCS dose or symptom-scores, but may affect the chance of complete response, that is no exacerbations or need for OCS
Read moreStevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 15-year Regional Burn Center Experience.